|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:availability
|
Prescription only
|
|
gptkbp:brand
|
gptkb:Equetro
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
Anticonvulsant
Mood stabilizer
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:contraindication
|
Hypersensitivity to lamotrigine
|
|
gptkbp:dosage_form
|
Extended-release tablet
|
|
gptkbp:duration
|
Long-term
|
|
gptkbp:excretion
|
Urine
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Equetro
|
|
gptkbp:ingredients
|
gptkb:Lamotrigine
|
|
gptkbp:interacts_with
|
gptkb:Oral_contraceptives
gptkb:Carbamazepine
gptkb:Phenytoin
gptkb:Valproate
Phenobarbital
|
|
gptkbp:is_monitored_by
|
Liver function tests
Skin reactions
Blood levels
|
|
gptkbp:lifespan
|
25 hours
|
|
gptkbp:manufacturer
|
gptkb:Sunovion_Pharmaceuticals
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:packaging
|
Blister pack
|
|
gptkbp:patient_population
|
gptkb:children
Adults
|
|
gptkbp:previous_name
|
gptkb:Lamotrigine
|
|
gptkbp:price
|
Varies by pharmacy
|
|
gptkbp:provides_guidance_on
|
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:American_Psychiatric_Association
|
|
gptkbp:route_of_administration
|
Oral
|
|
gptkbp:side_effect
|
gptkb:Insomnia
gptkb:Nausea
Dizziness
Headache
Rash
|
|
gptkbp:storage
|
Room temperature
|
|
gptkbp:strength
|
100 mg
200 mg
300 mg
|
|
gptkbp:symptoms
|
Seizures
Mood swings
|
|
gptkbp:type_of_care
|
Important for efficacy
|
|
gptkbp:used_for
|
Bipolar disorder
|
|
gptkbp:bfsParent
|
gptkb:carbamazepine
|
|
gptkbp:bfsLayer
|
5
|